Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Growth 2026-2032
The global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market size is predicted to grow from US$ 66.06 million in 2025 to US$ 787 million in 2032; it is expected to grow at a CAGR of 31.4% from 2026 to 2032.
A Drug-Eluting Resorbable Scaffold for Below-the-Knee (BTK) Arteries is an advanced bioresorbable vascular implant specifically developed to treat stenotic or occlusive lesions in below-the-knee arteries, particularly in patients with chronic limb-threatening ischemia (CLTI), severe peripheral artery disease and diabetes-related vascular complications. Delivered via balloon-expandable catheter technology, the scaffold provides temporary mechanical support to maintain vessel patency while locally releasing antiproliferative drugs, such as sirolimus or everolimus, to inhibit neointimal hyperplasia and reduce restenosis. After vascular healing and remodeling are completed, the scaffold gradually degrades and is absorbed by the body, eliminating the long-term presence of permanent metallic implants and potentially restoring more natural vascular physiology. A typical system consists of a bioresorbable scaffold platform, a drug-eluting coating, biodegradable polymer matrices and a dedicated delivery catheter. By integrating temporary vascular support, controlled drug release and bioresorption into a single platform, these devices represent one of the most innovative developments in peripheral vascular intervention, combining advances in biomaterials, drug-delivery technology and endovascular engineering.In 2025, global Drug-Eluting Resorbable Scaffold for Below-the-Knee (BTK) Arteries production reached approximately 32.1 k units.
The increasing prevalence of diabetes, rapid population aging and the growing burden of chronic limb-threatening ischemia are reshaping the global peripheral vascular intervention market. Compared with conventional balloon angioplasty and permanent metallic stents, drug-eluting bioresorbable scaffolds provide temporary vessel support while avoiding the long-term limitations associated with permanent implants, making them particularly attractive for small-caliber below-the-knee arteries. Government initiatives focused on diabetic foot management, updated vascular disease treatment guidelines and continuous investment by leading medical device companies in bioresorbable materials, controlled drug-delivery systems and next-generation scaffold technologies are accelerating innovation. As healthcare systems place greater emphasis on limb preservation, long-term vessel restoration and improved patient quality of life, BTK drug-eluting resorbable scaffolds are emerging as one of the most promising growth segments in peripheral vascular intervention.
Below-the-knee arteries present unique anatomical and pathological challenges, including small vessel diameters, diffuse calcification, long lesion lengths and complex bifurcation anatomy. Consequently, bioresorbable scaffolds must achieve an optimal balance between radial strength, flexibility, degradation kinetics and long-term safety. Maintaining sufficient mechanical support during vascular healing while ensuring predictable degradation without structural failure remains a significant engineering challenge. In addition, patients with CLTI frequently present with diabetes, renal insufficiency and multiple cardiovascular comorbidities, making clinical outcomes more difficult to evaluate and increasing the need for robust long-term clinical evidence. Market expansion is also influenced by regulatory approval pathways, reimbursement policies, physician training requirements and institutional procedural capabilities. Furthermore, competition from drug-coated balloons, drug-eluting metallic stents, covered stents and emerging vessel-restoration technologies will continue to shape the competitive landscape.
Clinical demand is evolving beyond immediate vessel recanalization toward comprehensive long-term vascular restoration, sustained limb salvage and reduced repeat interventions. Multidisciplinary collaboration among vascular surgeons, interventional cardiologists, interventional radiologists and diabetic foot specialists is becoming increasingly common, driving more standardized treatment pathways for complex below-the-knee disease. Future demand will favor integrated therapeutic platforms combining procedural simplicity, scaffold flexibility, controlled drug release and reliable bioresorption rather than focusing solely on acute technical success. Advances in intravascular imaging, artificial intelligence-assisted lesion assessment and precision endovascular planning are expected to further expand the role of drug-eluting bioresorbable scaffolds in treating complex lesions and high-risk patient populations, strengthening their position within the evolving peripheral vascular intervention market.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Industry Forecast” looks at past sales and reviews total world Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries sales in 2025, providing a comprehensive analysis by region and market sector of projected Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries sales for 2026 through 2032. With Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries industry.
This Insight Report provides a comprehensive analysis of the global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries.
This report presents a comprehensive overview, market shares, and growth opportunities of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market by product type, application, key manufacturers and key regions and countries.
A Drug-Eluting Resorbable Scaffold for Below-the-Knee (BTK) Arteries is an advanced bioresorbable vascular implant specifically developed to treat stenotic or occlusive lesions in below-the-knee arteries, particularly in patients with chronic limb-threatening ischemia (CLTI), severe peripheral artery disease and diabetes-related vascular complications. Delivered via balloon-expandable catheter technology, the scaffold provides temporary mechanical support to maintain vessel patency while locally releasing antiproliferative drugs, such as sirolimus or everolimus, to inhibit neointimal hyperplasia and reduce restenosis. After vascular healing and remodeling are completed, the scaffold gradually degrades and is absorbed by the body, eliminating the long-term presence of permanent metallic implants and potentially restoring more natural vascular physiology. A typical system consists of a bioresorbable scaffold platform, a drug-eluting coating, biodegradable polymer matrices and a dedicated delivery catheter. By integrating temporary vascular support, controlled drug release and bioresorption into a single platform, these devices represent one of the most innovative developments in peripheral vascular intervention, combining advances in biomaterials, drug-delivery technology and endovascular engineering.In 2025, global Drug-Eluting Resorbable Scaffold for Below-the-Knee (BTK) Arteries production reached approximately 32.1 k units.
The increasing prevalence of diabetes, rapid population aging and the growing burden of chronic limb-threatening ischemia are reshaping the global peripheral vascular intervention market. Compared with conventional balloon angioplasty and permanent metallic stents, drug-eluting bioresorbable scaffolds provide temporary vessel support while avoiding the long-term limitations associated with permanent implants, making them particularly attractive for small-caliber below-the-knee arteries. Government initiatives focused on diabetic foot management, updated vascular disease treatment guidelines and continuous investment by leading medical device companies in bioresorbable materials, controlled drug-delivery systems and next-generation scaffold technologies are accelerating innovation. As healthcare systems place greater emphasis on limb preservation, long-term vessel restoration and improved patient quality of life, BTK drug-eluting resorbable scaffolds are emerging as one of the most promising growth segments in peripheral vascular intervention.
Below-the-knee arteries present unique anatomical and pathological challenges, including small vessel diameters, diffuse calcification, long lesion lengths and complex bifurcation anatomy. Consequently, bioresorbable scaffolds must achieve an optimal balance between radial strength, flexibility, degradation kinetics and long-term safety. Maintaining sufficient mechanical support during vascular healing while ensuring predictable degradation without structural failure remains a significant engineering challenge. In addition, patients with CLTI frequently present with diabetes, renal insufficiency and multiple cardiovascular comorbidities, making clinical outcomes more difficult to evaluate and increasing the need for robust long-term clinical evidence. Market expansion is also influenced by regulatory approval pathways, reimbursement policies, physician training requirements and institutional procedural capabilities. Furthermore, competition from drug-coated balloons, drug-eluting metallic stents, covered stents and emerging vessel-restoration technologies will continue to shape the competitive landscape.
Clinical demand is evolving beyond immediate vessel recanalization toward comprehensive long-term vascular restoration, sustained limb salvage and reduced repeat interventions. Multidisciplinary collaboration among vascular surgeons, interventional cardiologists, interventional radiologists and diabetic foot specialists is becoming increasingly common, driving more standardized treatment pathways for complex below-the-knee disease. Future demand will favor integrated therapeutic platforms combining procedural simplicity, scaffold flexibility, controlled drug release and reliable bioresorption rather than focusing solely on acute technical success. Advances in intravascular imaging, artificial intelligence-assisted lesion assessment and precision endovascular planning are expected to further expand the role of drug-eluting bioresorbable scaffolds in treating complex lesions and high-risk patient populations, strengthening their position within the evolving peripheral vascular intervention market.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Industry Forecast” looks at past sales and reviews total world Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries sales in 2025, providing a comprehensive analysis by region and market sector of projected Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries sales for 2026 through 2032. With Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries industry.
This Insight Report provides a comprehensive analysis of the global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries.
This report presents a comprehensive overview, market shares, and growth opportunities of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Polylactic Acid-Based Resorbable Scaffolds
- Tyrosine-Derived Polycarbonate Scaffolds
- Composite Resorbable Scaffolds
- Other
Segmentation by Drug Coating:
- Sirolimus-eluting
- Everolimus-eluting
- Paclitaxel-eluting
- Other
Segmentation by Resorption Mechanism:
- Hydrolytically Degradable Polymer Scaffolds
- Corrosion-Based Metallic Scaffolds
- Enzymatically Degradable Scaffolds
- Combined Hydrolytic and Enzymatic Resorption
- Other
Segmentation by Application:
- Critical Limb-threatening Ischemia
- Below-the-knee Revascularization
- Diabetic Foot Vascular Treatment
- Peripheral Artery Disease
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Abbott
- BIOTRONIK
- REVA Medical
- Elixir Medical
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market?
- What factors are driving Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries market opportunities vary by end market size?
- How does Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Country/Region, 2021, 2025 & 2032
2.2 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Type
2.2.1 Polylactic Acid-Based Resorbable Scaffolds
2.2.2 Tyrosine-Derived Polycarbonate Scaffolds
2.2.3 Composite Resorbable Scaffolds
2.2.4 Other
2.2.5 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type
2.2.5.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
2.2.5.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Type (2021-2026)
2.3 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Drug Coating
2.3.1 Sirolimus-eluting
2.3.2 Everolimus-eluting
2.3.3 Paclitaxel-eluting
2.3.4 Other
2.3.5 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Drug Coating
2.3.5.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Drug Coating (2021-2026)
2.3.5.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Drug Coating (2021-2026)
2.3.5.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Drug Coating (2021-2026)
2.4 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Resorption Mechanism
2.4.1 Hydrolytically Degradable Polymer Scaffolds
2.4.2 Corrosion-Based Metallic Scaffolds
2.4.3 Enzymatically Degradable Scaffolds
2.4.4 Combined Hydrolytic and Enzymatic Resorption
2.4.5 Other
2.4.6 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Resorption Mechanism
2.4.6.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Resorption Mechanism (2021-2026)
2.4.6.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Resorption Mechanism (2021-2026)
2.4.6.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Resorption Mechanism (2021-2026)
2.5 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Application
2.5.1 Critical Limb-threatening Ischemia
2.5.2 Below-the-knee Revascularization
2.5.3 Diabetic Foot Vascular Treatment
2.5.4 Peripheral Artery Disease
2.5.5 Other
2.5.6 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application
2.5.6.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Market Share by Application (2021-2026)
2.5.6.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Application (2021-2026)
2.5.6.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Breakdown Data by Company
3.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales by Company (2021-2026)
3.1.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Company (2021-2026)
3.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue by Company (2021-2026)
3.2.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Company (2021-2026)
3.2.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Company (2021-2026)
3.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Company
3.4 Key Manufacturers Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Location Distribution
3.4.2 Players Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DRUG-ELUTING RESORBABLE SCAFFOLD FOR BELOW-THE-KNEE ARTERIES BY GEOGRAPHIC REGION
4.1 World Historic Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Size by Geographic Region (2021-2026)
4.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Size by Country/Region (2021-2026)
4.2.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales by Country/Region (2021-2026)
4.2.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue by Country/Region (2021-2026)
4.3 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
4.4 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
4.5 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
4.6 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
5 AMERICAS
5.1 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country
5.1.1 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026)
5.1.2 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026)
5.2 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
5.3 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Region
6.1.1 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Region (2021-2026)
6.1.2 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Region (2021-2026)
6.2 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
6.3 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Country
7.1.1 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026)
7.1.2 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026)
7.2 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
7.3 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Country
8.1.1 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026)
8.1.2 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026)
8.2 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
8.3 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
10.3 Manufacturing Process Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
10.4 Industry Chain Structure of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Distributors
11.3 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Customer
12 WORLD FORECAST REVIEW FOR DRUG-ELUTING RESORBABLE SCAFFOLD FOR BELOW-THE-KNEE ARTERIES BY GEOGRAPHIC REGION
12.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Size Forecast by Region
12.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Forecast by Region (2027-2032)
12.1.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Forecast by Type (2027-2032)
12.7 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Abbott
13.1.1 Abbott Company Information
13.1.2 Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.1.3 Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Abbott Main Business Overview
13.1.5 Abbott Latest Developments
13.2 BIOTRONIK
13.2.1 BIOTRONIK Company Information
13.2.2 BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.2.3 BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 BIOTRONIK Main Business Overview
13.2.5 BIOTRONIK Latest Developments
13.3 REVA Medical
13.3.1 REVA Medical Company Information
13.3.2 REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.3.3 REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 REVA Medical Main Business Overview
13.3.5 REVA Medical Latest Developments
13.4 Elixir Medical
13.4.1 Elixir Medical Company Information
13.4.2 Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.4.3 Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Elixir Medical Main Business Overview
13.4.5 Elixir Medical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Country/Region, 2021, 2025 & 2032
2.2 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Type
2.2.1 Polylactic Acid-Based Resorbable Scaffolds
2.2.2 Tyrosine-Derived Polycarbonate Scaffolds
2.2.3 Composite Resorbable Scaffolds
2.2.4 Other
2.2.5 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type
2.2.5.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
2.2.5.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Type (2021-2026)
2.3 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Drug Coating
2.3.1 Sirolimus-eluting
2.3.2 Everolimus-eluting
2.3.3 Paclitaxel-eluting
2.3.4 Other
2.3.5 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Drug Coating
2.3.5.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Drug Coating (2021-2026)
2.3.5.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Drug Coating (2021-2026)
2.3.5.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Drug Coating (2021-2026)
2.4 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Resorption Mechanism
2.4.1 Hydrolytically Degradable Polymer Scaffolds
2.4.2 Corrosion-Based Metallic Scaffolds
2.4.3 Enzymatically Degradable Scaffolds
2.4.4 Combined Hydrolytic and Enzymatic Resorption
2.4.5 Other
2.4.6 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Resorption Mechanism
2.4.6.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Resorption Mechanism (2021-2026)
2.4.6.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Resorption Mechanism (2021-2026)
2.4.6.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Resorption Mechanism (2021-2026)
2.5 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Segment by Application
2.5.1 Critical Limb-threatening Ischemia
2.5.2 Below-the-knee Revascularization
2.5.3 Diabetic Foot Vascular Treatment
2.5.4 Peripheral Artery Disease
2.5.5 Other
2.5.6 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application
2.5.6.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Market Share by Application (2021-2026)
2.5.6.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue and Market Share by Application (2021-2026)
2.5.6.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Breakdown Data by Company
3.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales by Company (2021-2026)
3.1.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Company (2021-2026)
3.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue by Company (2021-2026)
3.2.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Company (2021-2026)
3.2.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Company (2021-2026)
3.3 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Company
3.4 Key Manufacturers Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Location Distribution
3.4.2 Players Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DRUG-ELUTING RESORBABLE SCAFFOLD FOR BELOW-THE-KNEE ARTERIES BY GEOGRAPHIC REGION
4.1 World Historic Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Size by Geographic Region (2021-2026)
4.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Size by Country/Region (2021-2026)
4.2.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales by Country/Region (2021-2026)
4.2.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue by Country/Region (2021-2026)
4.3 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
4.4 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
4.5 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
4.6 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth
5 AMERICAS
5.1 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country
5.1.1 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026)
5.1.2 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026)
5.2 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
5.3 Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Region
6.1.1 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Region (2021-2026)
6.1.2 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Region (2021-2026)
6.2 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
6.3 APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Country
7.1.1 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026)
7.1.2 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026)
7.2 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
7.3 Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries by Country
8.1.1 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026)
8.1.2 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026)
8.2 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026)
8.3 Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
10.3 Manufacturing Process Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
10.4 Industry Chain Structure of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Distributors
11.3 Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Customer
12 WORLD FORECAST REVIEW FOR DRUG-ELUTING RESORBABLE SCAFFOLD FOR BELOW-THE-KNEE ARTERIES BY GEOGRAPHIC REGION
12.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market Size Forecast by Region
12.1.1 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Forecast by Region (2027-2032)
12.1.2 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Forecast by Type (2027-2032)
12.7 Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Abbott
13.1.1 Abbott Company Information
13.1.2 Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.1.3 Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Abbott Main Business Overview
13.1.5 Abbott Latest Developments
13.2 BIOTRONIK
13.2.1 BIOTRONIK Company Information
13.2.2 BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.2.3 BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 BIOTRONIK Main Business Overview
13.2.5 BIOTRONIK Latest Developments
13.3 REVA Medical
13.3.1 REVA Medical Company Information
13.3.2 REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.3.3 REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 REVA Medical Main Business Overview
13.3.5 REVA Medical Latest Developments
13.4 Elixir Medical
13.4.1 Elixir Medical Company Information
13.4.2 Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
13.4.3 Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Elixir Medical Main Business Overview
13.4.5 Elixir Medical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Polylactic Acid-Based Resorbable Scaffolds
Table 4. Major Players of Tyrosine-Derived Polycarbonate Scaffolds
Table 5. Major Players of Composite Resorbable Scaffolds
Table 6. Major Players of Other
Table 7. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 8. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Table 9. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Type (2021-2026) & ($ million)
Table 10. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Type (2021-2026)
Table 11. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of Sirolimus-eluting
Table 13. Major Players of Everolimus-eluting
Table 14. Major Players of Paclitaxel-eluting
Table 15. Major Players of Other
Table 16. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Drug Coating (2021-2026) & (K Units)
Table 17. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Drug Coating (2021-2026)
Table 18. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Drug Coating (2021-2026) & ($ million)
Table 19. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Drug Coating (2021-2026)
Table 20. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Drug Coating (2021-2026) & (US$/Unit)
Table 21. Major Players of Hydrolytically Degradable Polymer Scaffolds
Table 22. Major Players of Corrosion-Based Metallic Scaffolds
Table 23. Major Players of Enzymatically Degradable Scaffolds
Table 24. Major Players of Combined Hydrolytic and Enzymatic Resorption
Table 25. Major Players of Other
Table 26. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Resorption Mechanism (2021-2026) & (K Units)
Table 27. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Resorption Mechanism (2021-2026)
Table 28. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Resorption Mechanism (2021-2026) & ($ million)
Table 29. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Resorption Mechanism (2021-2026)
Table 30. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Resorption Mechanism (2021-2026) & (US$/Unit)
Table 31. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale by Application (2021-2026) & (K Units)
Table 32. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Market Share by Application (2021-2026)
Table 33. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Application (2021-2026) & ($ million)
Table 34. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Application (2021-2026)
Table 35. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Company (2021-2026) & (K Units)
Table 37. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Company (2021-2026)
Table 38. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Company (2021-2026)
Table 40. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Producing Area Distribution and Sales Area
Table 42. Players Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Products Offered
Table 43. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share Geographic Region (2021-2026)
Table 48. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country/Region (2021-2026)
Table 52. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026) & (K Units)
Table 55. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country (2021-2026)
Table 56. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 58. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 59. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Region (2021-2026) & (K Units)
Table 60. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Region (2021-2026)
Table 61. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 63. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 64. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026) & (K Units)
Table 65. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 67. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 71. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Table 73. Key Market Challenges & Risks of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Table 74. Key Industry Trends of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Table 75. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Distributors List
Table 78. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Customer List
Table 79. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Type (2027-2032) & (K Units)
Table 90. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Abbott Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 94. Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 95. Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Abbott Main Business
Table 97. Abbott Latest Developments
Table 98. BIOTRONIK Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 99. BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 100. BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. BIOTRONIK Main Business
Table 102. BIOTRONIK Latest Developments
Table 103. REVA Medical Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 104. REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 105. REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. REVA Medical Main Business
Table 107. REVA Medical Latest Developments
Table 108. Elixir Medical Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 109. Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 110. Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Elixir Medical Main Business
Table 112. Elixir Medical Latest Developments
Table 1. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Polylactic Acid-Based Resorbable Scaffolds
Table 4. Major Players of Tyrosine-Derived Polycarbonate Scaffolds
Table 5. Major Players of Composite Resorbable Scaffolds
Table 6. Major Players of Other
Table 7. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 8. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Table 9. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Type (2021-2026) & ($ million)
Table 10. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Type (2021-2026)
Table 11. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of Sirolimus-eluting
Table 13. Major Players of Everolimus-eluting
Table 14. Major Players of Paclitaxel-eluting
Table 15. Major Players of Other
Table 16. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Drug Coating (2021-2026) & (K Units)
Table 17. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Drug Coating (2021-2026)
Table 18. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Drug Coating (2021-2026) & ($ million)
Table 19. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Drug Coating (2021-2026)
Table 20. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Drug Coating (2021-2026) & (US$/Unit)
Table 21. Major Players of Hydrolytically Degradable Polymer Scaffolds
Table 22. Major Players of Corrosion-Based Metallic Scaffolds
Table 23. Major Players of Enzymatically Degradable Scaffolds
Table 24. Major Players of Combined Hydrolytic and Enzymatic Resorption
Table 25. Major Players of Other
Table 26. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Resorption Mechanism (2021-2026) & (K Units)
Table 27. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Resorption Mechanism (2021-2026)
Table 28. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Resorption Mechanism (2021-2026) & ($ million)
Table 29. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Resorption Mechanism (2021-2026)
Table 30. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Resorption Mechanism (2021-2026) & (US$/Unit)
Table 31. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale by Application (2021-2026) & (K Units)
Table 32. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Market Share by Application (2021-2026)
Table 33. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Application (2021-2026) & ($ million)
Table 34. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Application (2021-2026)
Table 35. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Company (2021-2026) & (K Units)
Table 37. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Company (2021-2026)
Table 38. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Company (2021-2026)
Table 40. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Producing Area Distribution and Sales Area
Table 42. Players Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Products Offered
Table 43. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share Geographic Region (2021-2026)
Table 48. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country/Region (2021-2026)
Table 52. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026) & (K Units)
Table 55. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country (2021-2026)
Table 56. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 58. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 59. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Region (2021-2026) & (K Units)
Table 60. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Region (2021-2026)
Table 61. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 63. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 64. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026) & (K Units)
Table 65. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 67. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Type (2021-2026) & (K Units)
Table 71. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Table 73. Key Market Challenges & Risks of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Table 74. Key Industry Trends of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Table 75. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Distributors List
Table 78. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Customer List
Table 79. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Type (2027-2032) & (K Units)
Table 90. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Abbott Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 94. Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 95. Abbott Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Abbott Main Business
Table 97. Abbott Latest Developments
Table 98. BIOTRONIK Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 99. BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 100. BIOTRONIK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. BIOTRONIK Main Business
Table 102. BIOTRONIK Latest Developments
Table 103. REVA Medical Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 104. REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 105. REVA Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. REVA Medical Main Business
Table 107. REVA Medical Latest Developments
Table 108. Elixir Medical Basic Information, Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Manufacturing Base, Sales Area and Its Competitors
Table 109. Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Product Portfolios and Specifications
Table 110. Elixir Medical Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Elixir Medical Main Business
Table 112. Elixir Medical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Figure 2. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country/Region (2025)
Figure 10. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Polylactic Acid-Based Resorbable Scaffolds
Figure 12. Product Picture of Tyrosine-Derived Polycarbonate Scaffolds
Figure 13. Product Picture of Composite Resorbable Scaffolds
Figure 14. Product Picture of Other
Figure 15. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type in 2026
Figure 16. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Sirolimus-eluting
Figure 18. Product Picture of Everolimus-eluting
Figure 19. Product Picture of Paclitaxel-eluting
Figure 20. Product Picture of Other
Figure 21. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Drug Coating in 2026
Figure 22. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Drug Coating (2021-2026)
Figure 23. Product Picture of Hydrolytically Degradable Polymer Scaffolds
Figure 24. Product Picture of Corrosion-Based Metallic Scaffolds
Figure 25. Product Picture of Enzymatically Degradable Scaffolds
Figure 26. Product Picture of Combined Hydrolytic and Enzymatic Resorption
Figure 27. Product Picture of Other
Figure 28. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Resorption Mechanism in 2026
Figure 29. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Resorption Mechanism (2021-2026)
Figure 30. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Critical Limb-threatening Ischemia
Figure 31. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Critical Limb-threatening Ischemia (2021-2026) & (K Units)
Figure 32. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Below-the-knee Revascularization
Figure 33. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Below-the-knee Revascularization (2021-2026) & (K Units)
Figure 34. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Diabetic Foot Vascular Treatment
Figure 35. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Diabetic Foot Vascular Treatment (2021-2026) & (K Units)
Figure 36. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Peripheral Artery Disease
Figure 37. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Peripheral Artery Disease (2021-2026) & (K Units)
Figure 38. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Other
Figure 39. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Other (2021-2026) & (K Units)
Figure 40. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Market Share by Application (2025)
Figure 41. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Application in 2025
Figure 42. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Company in 2025 (K Units)
Figure 43. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Company in 2025
Figure 44. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Company in 2025 ($ millions)
Figure 45. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Company in 2025
Figure 46. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Geographic Region (2021-2026)
Figure 47. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Geographic Region in 2025
Figure 48. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 49. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 50. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 51. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 52. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 53. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 54. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 55. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 56. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country in 2025
Figure 57. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country (2021-2026)
Figure 58. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 59. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 60. United States Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 61. Canada Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 62. Mexico Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 63. Brazil Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 64. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Region in 2025
Figure 65. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Region (2021-2026)
Figure 66. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 67. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 68. China Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 69. Japan Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 70. South Korea Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 71. Southeast Asia Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 72. India Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 73. Australia Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 74. China Taiwan Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 75. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country in 2025
Figure 76. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country (2021-2026)
Figure 77. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 78. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 79. Germany Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 80. France Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 81. UK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 82. Italy Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 83. Russia Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 84. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country (2021-2026)
Figure 85. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 86. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 87. Egypt Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 88. South Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 89. Israel Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 90. Turkey Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 91. GCC Countries Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 92. Manufacturing Cost Structure Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries in 2026
Figure 93. Manufacturing Process Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Figure 94. Industry Chain Structure of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Figure 95. Channels of Distribution
Figure 96. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Forecast by Region (2027-2032)
Figure 97. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share Forecast by Region (2027-2032)
Figure 98. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share Forecast by Type (2027-2032)
Figure 99. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share Forecast by Type (2027-2032)
Figure 100. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share Forecast by Application (2027-2032)
Figure 101. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Figure 2. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country/Region (2025)
Figure 10. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Polylactic Acid-Based Resorbable Scaffolds
Figure 12. Product Picture of Tyrosine-Derived Polycarbonate Scaffolds
Figure 13. Product Picture of Composite Resorbable Scaffolds
Figure 14. Product Picture of Other
Figure 15. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type in 2026
Figure 16. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Sirolimus-eluting
Figure 18. Product Picture of Everolimus-eluting
Figure 19. Product Picture of Paclitaxel-eluting
Figure 20. Product Picture of Other
Figure 21. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Drug Coating in 2026
Figure 22. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Drug Coating (2021-2026)
Figure 23. Product Picture of Hydrolytically Degradable Polymer Scaffolds
Figure 24. Product Picture of Corrosion-Based Metallic Scaffolds
Figure 25. Product Picture of Enzymatically Degradable Scaffolds
Figure 26. Product Picture of Combined Hydrolytic and Enzymatic Resorption
Figure 27. Product Picture of Other
Figure 28. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Resorption Mechanism in 2026
Figure 29. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Resorption Mechanism (2021-2026)
Figure 30. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Critical Limb-threatening Ischemia
Figure 31. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Critical Limb-threatening Ischemia (2021-2026) & (K Units)
Figure 32. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Below-the-knee Revascularization
Figure 33. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Below-the-knee Revascularization (2021-2026) & (K Units)
Figure 34. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Diabetic Foot Vascular Treatment
Figure 35. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Diabetic Foot Vascular Treatment (2021-2026) & (K Units)
Figure 36. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Peripheral Artery Disease
Figure 37. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Peripheral Artery Disease (2021-2026) & (K Units)
Figure 38. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Consumed in Other
Figure 39. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Market: Other (2021-2026) & (K Units)
Figure 40. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sale Market Share by Application (2025)
Figure 41. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Application in 2025
Figure 42. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales by Company in 2025 (K Units)
Figure 43. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Company in 2025
Figure 44. Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue by Company in 2025 ($ millions)
Figure 45. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Company in 2025
Figure 46. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Geographic Region (2021-2026)
Figure 47. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Geographic Region in 2025
Figure 48. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 49. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 50. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 51. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 52. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 53. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 54. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales 2021-2026 (K Units)
Figure 55. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue 2021-2026 ($ millions)
Figure 56. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country in 2025
Figure 57. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country (2021-2026)
Figure 58. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 59. Americas Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 60. United States Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 61. Canada Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 62. Mexico Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 63. Brazil Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 64. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Region in 2025
Figure 65. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Region (2021-2026)
Figure 66. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 67. APAC Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 68. China Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 69. Japan Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 70. South Korea Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 71. Southeast Asia Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 72. India Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 73. Australia Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 74. China Taiwan Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 75. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country in 2025
Figure 76. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share by Country (2021-2026)
Figure 77. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 78. Europe Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 79. Germany Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 80. France Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 81. UK Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 82. Italy Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 83. Russia Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 84. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Country (2021-2026)
Figure 85. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Type (2021-2026)
Figure 86. Middle East & Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share by Application (2021-2026)
Figure 87. Egypt Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 88. South Africa Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 89. Israel Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 90. Turkey Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 91. GCC Countries Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Growth 2021-2026 ($ millions)
Figure 92. Manufacturing Cost Structure Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries in 2026
Figure 93. Manufacturing Process Analysis of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Figure 94. Industry Chain Structure of Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries
Figure 95. Channels of Distribution
Figure 96. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Forecast by Region (2027-2032)
Figure 97. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share Forecast by Region (2027-2032)
Figure 98. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share Forecast by Type (2027-2032)
Figure 99. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share Forecast by Type (2027-2032)
Figure 100. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Sales Market Share Forecast by Application (2027-2032)
Figure 101. Global Drug-Eluting Resorbable Scaffold for Below-the-Knee Arteries Revenue Market Share Forecast by Application (2027-2032)
